Popular Blood Thinner May Reduce Liver Scarring for HCV Patients
August 12, 2008
Warfarin may prevent liver failure in hepatitis C patients
Warfarin could be used to prevent liver failure in thousands of patients with hepatitis C, a new study suggests.
UK researchers found that warfarin significantly reduced the level of liver fibrosis in mice with chronic liver injury.
Digital image analysis of liver histology of wild-type mice treated with warfarin showed a 33 per cent reduction in mean fibrosis area compared with controls, according to the study published in the Journal of Thrombosis and Haemostasis.
The alpha-smooth muscle actin, which is a biochemical marker of fibrosis at a cellular level, was also reduced by 10 per cent in wild-type mice treated with warfarin.
It follows previous research by the same group which found that patients prone to blood clotting who have hepatitis C have accelerated liver scarring.
The researchers have now begun a two-year multi-centre trial, funded by the Medical Research Council (MRC), in 90 hepatitis C patients who have had liver transplants. These patients suffer rapid progression to fibrosis, and the follow-up trial should bring faster results, the researchers say.
R1626 Could Help Defeat Hepatitis C
Early Hepatitis C Treatment Increases Success